Sangamo Therapeutics Inc (SGMO)
0.531
+0.01
(+1.72%)
USD |
NASDAQ |
May 03, 11:58
Sangamo Therapeutics Free Cash Flow: -246.00M for Dec. 31, 2023
Free Cash Flow Chart
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| December 31, 2023 | -246.00M |
| September 30, 2023 | -257.31M |
| June 30, 2023 | -265.30M |
| March 31, 2023 | -258.48M |
| December 31, 2022 | -243.80M |
| September 30, 2022 | -234.85M |
| June 30, 2022 | -241.44M |
| March 31, 2022 | -241.84M |
| December 31, 2021 | -256.53M |
| September 30, 2021 | -209.26M |
| June 30, 2021 | -115.58M |
| March 31, 2021 | 101.33M |
| December 31, 2020 | 155.16M |
| September 30, 2020 | 135.87M |
| June 30, 2020 | 63.80M |
| March 31, 2020 | -136.65M |
| December 31, 2019 | -165.08M |
| September 30, 2019 | -205.68M |
| June 30, 2019 | -199.53M |
| March 31, 2019 | -36.86M |
| December 31, 2018 | -6.515M |
| September 30, 2018 | 43.96M |
| June 30, 2018 | 64.43M |
| March 31, 2018 | 0.224M |
| December 31, 2017 | 7.428M |
| Date | Value |
|---|---|
| September 30, 2017 | 13.16M |
| June 30, 2017 | 11.81M |
| March 31, 2017 | -59.55M |
| December 31, 2016 | -66.62M |
| September 30, 2016 | -61.40M |
| June 30, 2016 | -58.11M |
| March 31, 2016 | -50.86M |
| December 31, 2015 | -33.72M |
| September 30, 2015 | -29.10M |
| June 30, 2015 | -20.52M |
| March 31, 2015 | -20.40M |
| December 31, 2014 | -5.675M |
| September 30, 2014 | -5.216M |
| June 30, 2014 | -3.914M |
| March 31, 2014 | -0.575M |
| December 31, 2013 | -19.91M |
| September 30, 2013 | -18.36M |
| June 30, 2013 | -19.06M |
| March 31, 2013 | -19.54M |
| December 31, 2012 | -8.805M |
| September 30, 2012 | -8.871M |
| June 30, 2012 | -10.26M |
| March 31, 2012 | -11.75M |
| December 31, 2011 | -26.47M |
| September 30, 2011 | -28.90M |
Free Cash Flow Range, Past 5 Years
-265.30M
Minimum
Jun 2023
155.16M
Maximum
Dec 2020
-148.48M
Average
-209.26M
Median
Sep 2021
Free Cash Flow Benchmarks
| AIM ImmunoTech Inc | -21.85M |
| Perspective Therapeutics Inc | -37.98M |
| Protalix BioTherapeutics Inc | -2.467M |
| Electromed Inc | 3.653M |
| Armata Pharmaceuticals Inc | -55.57M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | -50.54M |
| Cash from Investing (Quarterly) | 37.71M |
| Cash from Financing (Quarterly) | 0.167M |
| Free Cash Flow Per Share (Quarterly) | -0.2995 |
| Free Cash Flow to Equity (Quarterly) | -53.21M |
| Free Cash Flow to Firm (Quarterly) | -53.21M |
| Free Cash Flow Yield | -265.4% |